Trump administration move to reclassify cannabis sparks confusion

Key Points:

• The Trump administration has partially rescheduled cannabis by moving state-licensed medical cannabis products and prospective FDA-approved cannabis products from Schedule I to Schedule III, signaling a limited federal recognition of medical cannabis.
• The order does not broadly reschedule marijuana and raises concerns about predetermining scheduling outcomes for future FDA-approved cannabis drugs without full evidence-based evaluations.
• The partial rescheduling is justified by compliance with the Single Convention on Narcotic Drugs, a UN treaty, but critics argue this creates confusion and highlights a disconnect between federal policy and state legalization efforts.
• Industry experts criticize the move as confusing and politically motivated ahead of midterm elections, while acknowledging it offers some positive signals for medical cannabis providers but leaves many questions about implementation and equity unresolved.
• The new policy disproportionately benefits medical cannabis providers, often white entrepreneurs, while excluding many Black and Latino entrepreneurs who hold adult-use licenses, and full rescheduling remains uncertain with a DEA hearing scheduled for June 29.